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Abstract
Aim. This work aimed to validate an assay procedure for desloratadine tablets by direct spectrophotometric method.
Materials and methods. A pilot-scale batch of the pharmaceutical preparation Alerdez, film-coated tablets containing 5 mg 
of desloratadine, manufactured by PJSC SIC «Borshchahivskiy CPP», Ukraine, was used as an object of the study. A UV-Vis spectro-
photometer Lambda 25 (Perkin Elmer), analytical balance Mettler Toledo XP 205DR, and class A volumetric apparatus were used 
in the study. Validation of the procedure was performed following the metrological approach of the State Pharmacopoeia of Ukraine 
(SPhU), whose requirements for the target uncertainty and bias, which rest on the risk assessment of making incorrect decisions on 
compliance (a confidence level of 95 %), were translated into criteria for all validation characteristics recommended by ICH. All 
calculations were made in normalised coordinates. The linearity, accuracy and precision (repeatability) were studied in a single 
experiment using nine different concentrations that uniformly covered the range of ±30 % from the nominal concentration of deslo-
ratadine. For validation of the procedure, an SPhU reference standard of desloratadine was used. 
Results. The experiment design and validation characteristics being tested were in full compliance with ICH Q2(R1) recom-
mendations. All performance characteristics conformed to the criteria recommended by the SPhU. Requirements for the target un-
certainty (1.6 %) and bias for any systematic source of variation (≤ 0.51 %, negligible in relation to 1.6 %) were established. The 
analytical procedure was specific – the absorbance from the placebo solution was insignificant (A % = 0.36). The procedure met the 
requirements for linearity, accuracy, and precision at the repeatability level. The residual standard deviation s0 was 0.34 (≤ 0.84); 
correlation index Rc was 0.9998 (≥ 0.9991); intercept а was 0.045 (less than its confidence interval ∆a = 1.14). The confidence interval 
for recovery ∆Z, which was used as a precision estimate, was 0.55 % (less than the target uncertainty). The mean recovery, which was 
used as an accuracy estimate, statistically insignificantly deviated from 100 % (|Zmean–100| = 0.022 %). The confidence interval for the 
intermediate precision ∆intra was 0.33 % (less than the target uncertainty). The developed analytical procedure was found to be robust.
Conclusions. A spectrophotometric procedure suitable for the assay of desloratadine in film-coated tablets Alerdez with 
content limits of ±5 % was validated by the SPhU approach. 
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1. Introduction
Desloratadine (8-Chloro-6,11-dihydro-11-(piperidine-4-ylidene)-5H-benzo[5,6]cyclohep-
ta[1,2-b]pyridine; CAS 100643-71-8) is used for the relief of symptoms of seasonal allergic rhinitis, 
perennial (non-seasonal) allergic rhinitis, and the symptomatic treatment of pruritus and urticaria 
(hives) associated with chronic idiopathic urticarial, usually in the pharmaceutical formulations of 
tablets, syrups and solutions [1].
Desloratadine can be easily determined by the direct absorption spectrophotometry (SP) 
in the UV region due to the strong absorption of desloratadine solutions [2]. The substance of de-
sloratadine is described in the European Pharmacopoeia (Ph. Eur.) and the United States Pharma-
copeia (USP). The USP also has monographs «Desloratadine Tablets» and «Desloratadine Orally 
Disintegrating Tablets». The method of liquid chromatography with UV detector is used for deslo-
ratadine assay in all abovementioned monographs. It has potential advantages since, as a rule, 
it is a stability-indicating method. On the other hand, the SP method of desloratadine assay has an 
asset of being a faster method, which is especially valuable for pharmaceutical companies for both 
in-processing control and batch release. 
An analytical procedure must be validated before its implementation into routine use. The 
methodology of the analytical procedure validation described in the ICH Guide Q2(R1) «Vali-
dation of analytical procedures: text and methodology» is generally accepted [3]. The aim of 
the validation is to demonstrate the suitability of the procedure for its intended use. However, 
ICH Q2(R1) and other regulatory documents (namely, recommendations of the EDQM [4], USP [5], 
and WHO [6], which, despite having a different content, follow the ICH guide) do not specify cri-
teria for demonstrating such suitability. 
The concept of the uncertainty of measurement result is generally recognised as a scientific 
basis for applied metrology. The importance of the uncertainty concept for the pharmaceutical 
sector is emphasised in scientific articles, e. g. in work [7]. Recently, the USP Expert Panel has 
proposed a life cycle approach to validation that is based on the uncertainty concept [8] but does 
not follow the ICH recommendations. Similarly, based on the uncertainty approach [9], the new 
concept of Analytical Quality by Design provides only general principles for quality assurance. 
It should be noted that the uncertainty concept is now widely applied in analytical chemistry [10]. 
It takes into account the risk of making an incorrect conclusion on specification compliance at the 
accepted level of reliability [11]. The uncertainty concept can be correctly implemented in the phar-
maceutical sector only if internationally accepted standardisation rules are considered [12]. The 
decision rules take account of the fact that all sources of variability associated with the analytical 
result, technology, stability changes, etc., are included in the specifications. As a result, a decision 
on compliance is taken simply on the basis whether an analytical result meets specifications. The 
uncertainty approach can be correctly used for such a straightforward decision rule providing that 
variability of the analytical assay result for the finished preparation is insignificant in comparison 
with the two-sided specification width [12]. Based on these principles, the State Pharmacopoeia 
of Ukraine (SPhU) established requirements for the target uncertainty for main pharmaceutical 
tests that depend on the specification width and vary for assays of finished drug products and sub-
stances [13]. After public discussion in the journal «Farmacom» [14], an approach to the analytical 
procedure validation was introduced in the State Pharmacopoeia of Ukraine [15]. In fact, the SPhU 
approach formulated the Target Analytical Profile for the analytical procedure, which was later 
proposed by the USP as part of the novel concept of Lifecycle Management of Analytical Proce-
dures [8], which was then issued as a draft to the USP monograph [16]. The life cycle approach 
states that ICH validation characteristics are important and necessary to meet the required level 
of quality of the data [17] but do not provide recommendations for validation criteria. In contrast, 
the SPhU approach translates requirements for the target uncertainty and bias into criteria for all 
performance characteristics recommended in Q2(R1).
Although there is a number of papers dedicated to the development and validation of the SP 
assay of desloratadine in tablets, we met only one that employed the uncertainty concept [18], but 
only to estimate the uncertainty of measurement for the procedure being developed rather than to 
demonstrate the suitability of the procedure for the intended use by comparison of the validation 
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results with criteria set in advance. Therefore, it is topical to assess the suitability of the analytical 
procedure intended for SP assay of desloratadine by the SPhU approach, i.e. based on the measure-
ment uncertainty concept and risk assessment of making a wrong decision about the compliance 
with specifications.
The objective of this work is to validate a procedure for assay of desloratadine in 
film-coated tablets (tablet strength 5 mg, content limits of desloratadine ±5 %) produced by 
PJSC SIC «Borshchahivskiy CPP», Ukraine, following the requirements of the SPhU.
2. Materials and methods 
2.1. Test object
A pilot-scale batch of Alerdez (Lot No. Е01), 5 mg desloratadine film-coated tablets produced 
by «Borshchahivskiy CPP», Ukraine, served as an object of the study. The content of desloratadine 
per tablet is specified 5 mg ± 5 % (from 4.75 mg to 5.25 mg). The weight of one tablet is about 105 mg.
Excipients: calcium hydrogen phosphate dihydrate, cellulose, maise starch, talc, hypromel-
lose, macrogol 400 (PEG 400), macrogol 4000 (PEG 4000), polyvinyl alcohol, titanium dioxide, 
indigo-carmine colouring.
2.2. Reference standards and reagents
A desloratadine reference standard of the State Pharmacopoeia of Ukraine suitable for SP 
assay was used (the assigned value: 99.7 %; target uncertainty: 0.5 %, expressed as a one-sided 
confidence interval for a reliability level of 95 %). 
All reagents used in the study met the requirements of the Ph. Eur.
The desloratadine stock solution (1 mg/mL) was prepared for the linearity and stability studies. 
It was also used for the preparation of model solutions by the gravimetric method. 
2.3. Equipment
The spectrophotometers Lambda 25 and Lambda 35* equipped with a 1-cm cuvette (Per-
kin Elmer), analytical balances Mettler Toledo XP 205DR and Kern ABS 220-4*, pH-meter 
Metrohm, Class A volumetric pipettes and flasks, PTFE filter with pre-filter 0.45 mm 
cat. No. SYTG0602MNXX104 manufactured by MDI were used in the study. 
*Note: these were used additionally in the inter-laboratory precision experiment.
3. Results
3.1. An analytical procedure being validated
The text of the analytical procedure is given below.
Test solution. Grind 20 tablets to a visually homogeneous mass. Dilute 105 mg of the ob-
tained sample in 250 mL of 0.1 M hydrochloric acid, keeping it in an ultrasonic bath for 15 minutes, 
and filter.
Reference solution. Dissolve 40 mg of the desloratadine reference standard in 100 mL of 0.1 M 
hydrochloric acid. Dilute 5.0 mL of the obtained solution in 100 mL of 0.1 M hydrochloric acid.
Measure the absorbance at a wavelength of 282 nm.
The length of the optical path: 10 mm. 
The compensation solution: 0.1 М hydrochloric acid.
The content of desloratadine (X2) per tablet (in mg) is calculated by the formula: 
 X
A m P b
A m







100 100 100 800
=
´ ´ ´ ´ ´





where A1 – absorbance of the test solution; A0 – absorbance of the reference solution; m0 – test 
portion of the desloratadine reference standard, in mg; m1 – test portion of the sample obtained by 
tablet grinding, in mg; P – assigned value of desloratadine in the reference standard, in per cent; 
b – average mass of tablets, in mg.
For the nominal concentration of desloratadine (0.02 mg/mL), the absorbance is about 
0.64 absorption units (AU). 
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3.2. Design of the validation experiment and criteria
The detailed explanation of the theoretical principles of the SPhU approach is given in the 
monograph [19].
3.2.1. The target uncertainty of analytical results
Under the SPhU approach [11], the target uncertainty for assays of finished drug pro-
ducts (maxDAs) should be insignificant compared to the width of two-sided specifications: 
 max . ,DAs B= ´0 32  (2)
where B – half-width of content limits; maxDAs – target uncertainty.
Hereafter under an expanded uncertainty, we understand a 95 % one-sided confidence interval. 
The coefficient of 0.32 provides a 95 % reliability of making a correct decision on comp-
liance [13, 19]. 
Then, for desloratadine tablets as a finished drug product with the content limits of ±5 %, 
the requirement for insignificance takes the following form:
 max . %.DAs = 1 6  (3)
3.2.2. Use of normalised coordinates
When using normalised coordinates, we assume that during routine analysis, a single refe-
rence solution is used for calibration, i. e. the calibration curve passes through the origin.
















= ´100 %,  (4)
where Ci – concentration of the analyte in the i-th model solution being analysed; Cst – concentra-
tion of the analyte in the reference solution; Ai – analytical signal of the analyte for the i-th model 
solution being analysed; Ast – analytical signal of the analyte for the reference solution.
The concentration of the analyte in the reference solution should be close to the nominal 
concentration.
In normalised coordinates, for the calibration curve that passes through the origin, Z is the 
recovery expressed in per cent.
All further calculations are carried out in the normalised coordinates.
3.2.3. Criteria for performance characteristics
Specificity
According to the SPhU approach, bias caused by the additional absorbance of the placebo 
components (dplacebo) should be insignificant in relation to maxDAs:
 d placebo As,% . max .≤ ´0 32 D  (5)
For content limits of ±5 %, the requirement for the insignificance of dplacebo is expressed 
as follows:
 d placebo ≤ 0 51. . (6)
3.2.3.1. Range
By the ICH recommendations [3], the range of the linearity study in coordinates (Xi, Yi) 
should be not less than 80–120 % for assay and not less than 70–130 % for the content uniformity. 
Since the procedure is intended to be used for the assay and content uniformity, the range 
of 70–130 % and the most stringent acceptance criteria as for the assay with content limits 
of ±5 % (maxDAs = 1.6 %) are applied.
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3.2.3.2. Linearity, accuracy, precision (repeatability)
The linearity, accuracy, and precision (at the repeatability level) are studied simultaneously 
for nine concentrations, evenly distributed across the range, which complies with the ICH recom-
mendations for precision at the repeatability level. Actual concentrations that were studied are 
given in Table 1 in normalised coordinates. 
Linearity – the requirement for the residual standard deviation s0
The residual standard deviation s0 characterises a dispersion of the points around the line. 
Since each point can be treated as an individual analytical result, s0 in the normalised coordinates 
is RSD for the standard uncertainty of analytical results. Therefore, the confidence interval calcu-
lated from so should not exceed maxDAs, i. e.: 
 t g s As(95 %, 2)− ´ ≤0 max ,D  (7)
where g is the number of model solutions.
For g = 9 and content limits of ± 5 %, the requirement takes the following form:
 s0 1 6 0 84≤ ≤. / . .1.8946  (8)
Linearity – the requirement for the correlation index Rc


























where Xi – concentration of the i-th model solution used for the linearity study, in per cent of the 
nominal concentration; g – number of the model solutions. 
Due to the relative complexity of the mathematical expression of the Pearson coefficient, it 
is difficult to formulate the requirements connecting the values of r with the requirements for the 
uncertainty of the analysis results [20]. Yet it is easy to develop requirements for Rc based on those 
for maxDAs. Unlike the Pearson coefficient, which is only applicable to the linear regression, Rc can 
be used for any regression. 











SDrange is calculated from the actual concentrations of model solutions.
Linearity – the requirement for the intercept (а)
For the intercept (а), a two-level criterion is used.
The statistically insignificant difference from zero: the value of a should be less than its 
confidence interval.
Therefore, for g = 9, statistical insignificance can be expressed as follows:
 a t g s≤ − ´( %, ) ;95 2 0  a s≤ ´18946 0,  (12)
where sa is the standard deviation of the intercept of the line (a) obtained by the least-squares method.
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The practically insignificant difference from zero: the value of a should be practically insig-
nificant for the intended use of the procedure if the bias due to non-passage of the calibration curve 
through the origin does not exceed 0.32×maxDAs. 
For the symmetric range of application of the procedure, the criterion of practical insignifi-














where Хmin is the minimum limit of the procedure application range.
The criterion of practical insignificance (11) is only used in the event when the criterion of 
statistical insignificance (10) is not met.
For the content limits of ±5 % and the range of 70–130 %, the requirement takes the fol-
lowing form:
 a ≤ 1 71. .  (14)
Precision – estimation from the linearity data
For the estimation of the procedure precision from the linearity study, Zi values are used:
 DZ Z Zt g SD SD= − ´ = ´( %, ) . .95 1 1 8595  (15)
The following relationship must be fulfilled:
 D DZ As≤ max .  (16)
For content limits of ±5 %, the requirement takes the following form:
 DZ ≤ 1 6. %.  (17)
Accuracy – estimation from the linearity data
Bias (d) of the analytical results is defined as follows:
 d % .= −Z 100  (18)
By the SPhU approach, bias should be insignificant for spectrophotometric assay.
For accuracy estimation, a two-level criterion is used.






where g is the number of solutions used for the accuracy study from the linearity data.
For g = 9 and content limits of ±5 %, the following requirement for bias should be met:
 d ≤ DZ 3.  (20)
Practical insignificance: if the failure to comply with the requirements for statistical insig-
nificance is observed, the practical insignificance δ should be checked:
 d ≤ ´0 32. max .DAs  (21)
For content limits of ±5 %, the requirement for the practical insignificance is expressed 
as follows:
 d ≤ 0 51. .  (22)
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3.2.3.3. Intermediate precision 
For the intermediate precision, we use the approach based on the SPhU concept, which is 
described in detail in our paper [15]. Analyse the same sample of ground tablets on m ≥ 2 different 
days. Prepare n ≥ 5 of independent test solutions each day, and analyse them varying the factors 
that could affect precision as much as possible (different analysts, equipment, etc.). If all factors 
affecting precision are insignificant, all the results must belong to the same population. Therefore, 
for all obtained assay results (Zi), the mean (Zintra), standard deviation (SDZintra %), and relative 
confidence interval (∆intra %) are calculated:
 D intra Zt n m SD intra= ´ −[ ] ´95 1%, ( ) ,  (23)
 ∆intra should not exceed ΔAs, (24)
 D Dintra As≤ max .  (24)
For content limits of ±5 %, the requirement (25) takes the following form:
 D intra ≤ 1 6. %.  (25)
3.2.3.4. Robustness – stability of solutions
Based on the SPhU concept, we propose the following approach to stability studying.
Prepare a test solution according to the procedure. Prepare a reference solution with precise-
ly known concentrations of analyte («zero» solutions). Use the gravimetric method for dilutions. 
Assay the solutions («zero» time). After a predetermined period (we propose to check stability 
in N = 5 h, 24 h and 48 h after «zero» solutions preparation), prepare a fresh reference solution in 
the same manner (N-th solution). At the specified time, analyse both of the «zero» solutions using 
a fresh reference solution. Express results in per cents in relation to «added» amount for «zero» 
reference solution and in relation to «found» amount for «zero» test solution (ZN); the desloratadine 
content in «zero» solutions is taken as 100 %. Calculate differences in concentrations (100 % –ZN). 
The solutions are stable as long as the difference is insignificant in relation to maxDAs:
 100 0 32% . max .− ≤ ´ZN AsD  (26)
Since the specific absorbance of degradation products may differ from one of the analytes 
upward and downward, the difference modulus is used.
For content limits of ±5 %, the requirement (26) is expressed as follows:
 DStab(%) . .≤ 0 51  (27)
This approach allows us to confirm the stability of the solutions for quite a long period of 
time, which may be critical for a laboratory when investigating the OOS situation. However, the ne-
cessity to prepare solutions with the precisely known concentrations may be seen as a disadvantage. 
3.2.3.5. Robustness – the reliability of the analysis with respect to deliberate variations 
in method parameters
The solubility of desloratadine is increased in acidic water solutions in comparison with 
pure water. The UV spectrum of desloratadine is also affected by pH of water diluent [18]. Conse-
quently, it is reasonable to investigate the impact of HCl concentration variation in the diluent on 
the reference solution extinction and desloratadine recovery from the test portion of ground tablets.
For the prognosis of the «worst case» of 0.1 N⋅HCL concentration variability in the routine 
analysis, the uncertainty of the laboratory procedure of 0.1 N⋅HCl preparation was estimated per 
the SPhU recommendations. It comprised of about 2 %. On that basis, according to the SPhU in-
significance principle, an analytical procedure will be robust if the influence of HCl concentration 
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variability in the diluent on the reference solution absorbance is still insignificant for the range 
of HCl concentration of ±2 %´3.2 = ±7 % from the nominal concentration of 0.1 N·HCl. Following 
the same principle, the impact of HCl concentration variability is insignificant if the absorbance 
for reference solutions prepared using 0.093 N·HCl and 0.107 N·HCl does not differ from the ab-
sorbance of the reference solution prepared using 0.1 N·HCl by more than 0.51 %. In the same way, 
the variability of HCl concentration in the diluent has an insignificant impact on the desloratadine 
recovery if the «found» value for any test solutions prepared using 0.093 N·HCl, 0.1 N·HCl and 
0.107 N·HCl does not deflect by more than 0.51 from the «true» value that should be obtained 
with the nominal HCl concentration. It means that the difference between «found» values for any 
two solutions must not exceed 0.51 % ´ Ö2 = 0.74 %, because both experimental values vary inde-
pendently and can have uncertainty that should not exceed 0.51.
3.3. Experimental results 
UV spectra of the reference solution, test solution, model solution, and placebo solution are 
given in Fig. 1.
Fig. 1. Specificity study: the UV spectrum of (A) Placebo Solution, (B) Desloratadine Reference 
Solution, (C) Test Solution, (D) Model Solution.
3.3.1. Specificity
The test solution prepared from the ground tablets for the stability evaluation, the «100 %» 
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The extinction of this solution was recalculated per the nominal concentration of the deslo-
ratadine as follows:
 ANom = ARef ´ CNom/CRef. (28)
Then two solutions of placebo were prepared and measured following the procedure. 
The results of the specificity evaluation are shown in Table 1.
Table 1
Demonstration of specificity – the influence of the placebo absorption
Recalculation of the extinction for the reference solution
Reference solution АNom (282 nm), СNom = 0.020 mg/mL
АRef (282 nm) 0.685
0.6447
СRef, mg/mL 0.02125
Evaluation of the placebo influence
А, 282 nm А, 282 nm, mean Placebo influence, % (δplacebo)
Placebo solution 1 0.0023
0.0023
0.36Placebo solution 2 0.0023
Reference solution 100 % 0.6447 –
Criteria of insignificance ≤ 0.51 %
The validation requirements for the specificity of the procedure are met.
3.3.2. Linearity. Accuracy. Precision
Results of the analysis of model solutions are given in Table 2.
Table 2
Results of linearity, accuracy, and precision 
Solutions Concentration, mg/mL A, mean for 3 measurements Amount added (Xi) Amount found (Yi) Recovery (Zi)
Test 1 0.014076 0.455 66.24 66.42 99.86
Test 2 0.015999 0.515 75.29 75.18 99.89
Test 3 0.016925 0.545 79.65 79.56 100.09
Test 4 0.018039 0.582 84.89 84.96 100.05
Test 5 0.020143 0.650 94.79 94.84 99.94
Test 6 0.021771 0.701 102.45 102.38 100.46
Test 7 0.023294 0.754 109.62 110.12 99.42
Test 8 0.024296 0.779 114.33 113.67 100.21
Test 9 0.026271 0.849 123.63 123.89 100.28
For the obtained results, the parameters of the linear relationship were calculated by the 
least-squares method:
 Y a b Xi i= + ´ ,  (29)
where Yi – concentrations of the model solutions, in normalised coordinates; Xi – absorbance of the 
model solutions, in normalised coordinates; a – intercept; b – slope.
The graph of the linear relationship is shown in Fig. 2.
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Fig. 2. The linear relationship between normalised concentrations (X ) and normalised 
absorbance (Y ) for desloratadine model solutions from the linearity study
Linearity
Results of the calculation of parameters of the linear relationship between normalised con-
centrations (X ) and normalised absorbance (Y ) for model solutions of desloratadine and their as-
sessment are shown in Table 3.
Table 3
Results of the linearity study
Parameters Values Criterion 1: Requirement of statistical insignificance 
Criterion 2: Requirement of 
practical insignificance Conclusion
b 0.9997
a |0.045| ≤ 1.14 ≤ 1.71 Satisfies criterion 1
sa 0.60
s0 0.34 ≤ 0.84 Satisfies
SDrange 20.16
RС 0.9998 ≥ 0.9991 Satisfies
The validation requirements for the linearity of the procedure are met.
Precision and accuracy
The assessment results of the procedure precision and accuracy from the linearity data are 
shown in Table 4.
Table 4 
Results of the study of accuracy and precision 
Parameters Values Criterion 1: Requirement of statistical insignificance 
Criterion 2: Requirement 
of practical insignificance Conclusion
Precision DZ 0.55 ≤ 1.6 Satisfies
Accuracy |Zmean–100| |0.022| ≤ 0.185 ≤ 0.51 Satisfies criterion 1
The validation requirements for precision and accuracy of the procedure are met.
3.3.3. Intermediate precision 
Test solutions were prepared by the procedure described in Section 2 Materials and methods. 
Test portions for the assay on the 1st and 2nd days were taken from the same sample of ground 
tablets. Different analysts conducted an analysis on the 1st and 2nd day, using different reagents, 
volumetric glassware, filters, balances, ultrasonic baths, and spectrophotometers.
The results of the intermediate precision study are shown in Table 5.
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Table 5
Results of the intermediate precision study
Desloratadine content found, mg







Zintra = 100.6 SDZintra = 0.184 t (95 %; f = 11) = 1.7956 ∆intra = 0.33 Criterion: ∆intra ≤ 1.6 %
The validation requirements for the intermediate precision of the analytical procedure are met.
3.3.4. Robustness – stability of the solutions
For the preparation of the test solution, the ground tablets of desloratadine were used as 
described in Section 3.3.3 Intermediate precision.
The solutions were stored at 20 °С, protected from direct sunlight.
The results of the stability study of the solutions are shown in Table 6.
Table 6
Results of the stability study
Solution Parameter
Time (N), h 
5 24 48
Reference solution Z, % 100.09 99.74 100.11
100 % –Z –0.09 0.26 –0.11
Test solution Z, % 100.14 99.99 100.16
100 % –Z –0.14 0.009 –0.16
Criterion of insignificance: ç100–Z ç ≤ 0.51 %
Validation requirements for stability of the solutions are met when analysed in 24 h. 
3.3.5. Robustness – reliability of the analysis with respect to deliberate variations in 
the method parameters
The stock solution of desloratadine with concentration about 50 mg/50 mL in 0.1 N·HCl was 
prepared. The diluents with HCl normality of 0.093 and 0.107 were prepared. The reference solu-
tions for the evaluation of the impact of HCl concentration in the diluent on the reference solution 
extinction were prepared as follows: 5.0 mL (weighed) of the stock solution were diluted to 250 mL 
using 0.093 N·HCl, 0.107 N·HCl, and 0.1 N·HCl as diluents. The absorbance of the prepared solu-
tions was measured as described in the analytical procedure. Then, the absorbance of the reference 
solutions that were prepared using 0.093 N·HCl and 0.107 N·HCl (Ainit) were recalculated per the 
concentration of reference solution with the nominal concentration of HCl (Anom) by the formula:
 A A m mrecalc init nom init= ´ ,  (30)
where m – weights of aliquots of the reference solutions.
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The results of the impact of the diluent normality on the desloratadine spectra are shown 
in Table 7. 
Table 7
Recalculated absorbance of reference solutions for the assessment of the impact of HCl normality in the 
diluent on the desloratadine spectrum
Solution Absorbance, А Difference, %
Reference solution (0.1 N HCl) 0.640 –
Reference solution (0.093 N HCl) 0.641 0.16 %
Reference solution (0.107 N HCl) 0.640 0 %
Criterion Difference, % ≤ 0.51
Three test solutions were prepared using 0.093 N·HCl, 0.1 N·HCl, and 0.107 N·HCl as 
a diluent. The ratios of absorbance to the test portions were calculated for each test solution (A/m). 
As was substantiated above, the obtained values for the test solutions prepared using 0.093 N·HCl, 
and 0.107 N·HCl must not deviate from the value obtained for test solution prepared using 0.1 HCl 
by more than 0.74 %. The results are shown in Table 8.
Table 8
Ratios of absorbance to the test portions for test solutions for the assessment of the impact of HCl normality 
in the diluent on the recovery of desloratadine from ground tablets
Diluent Sample portion, m (mg) Absorbance of the test solution, A Ratio А/m Difference, %
0.1 N⋅HCl 410.5 0.6175 0.00150 –
0.093 N⋅HCl 400.6 0.6003 0.00150 0 %
0.107 N⋅HCl 415.2 0.6251 0.00151 0.67 %
Criterion Difference, % ≤ 0.72
Evidently, the analytical procedure is robust regarding the deliberate variation of HCl con-
centration in the diluent.
4. Discussion 
The validation results show that the analytical procedure is suitable for the intended use by 
the SPhU metrological criteria. 
It should be noted that even though the SPhU metrological criteria were developed based on 
the ICH recommendations, the ICH approach itself does not allow making a conclusion about the 
suitability of the analytical procedure as it does not specify what the suitability of the analytical 
procedure for the use for a given application is. Therefore, from our point of view, all validation 
studies that are based only on ICH recommendations list the research results without the scientifi-
cally sound justification of suitability. The concept of uncertainty made it possible to formulate an 
idea of demonstrating the fitness of the procedure for its intended purpose, based on which the SPhU 
translated all ICH recommendations into criteria thus providing scientific justification to that idea. 
Based on the uncertainty concept, the life cycle approach proposed later by the USP re-
cognised the importance of ICH recommendations but did not translate them into criteria for ICH 
validation characteristics [17]. As a result, this approach is still separated from the internationally 
accepted ICH recommendations and even has some contradictions with them. 
On the other hand, the USP approach has strongly criticised the one of ICH for being 
a formal check-box exercise that does not bear in mind the risk of incorrect decision-making in the 
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routine application of the analytical procedure and not leading to the reliable understanding and 
control of the variability sources [8, 17], which, in fact, is also applicable to the SPhU. 
In contrast to the ICH approach, USP proposed to use powerful tools for the quality as-
surance of the analysis result developed for the control of manufacture process (Lifecycle, Target 
Profile, Risk Management, Control Strategy, Knowledge Management, and Quality by Design) that 
enormously strengthen the effectiveness of the analytical validation process. 
Study limitations. The validation experiment design was developed by the SPhU approach 
for pharmaceutical preparation «Alerdez», 5 mg desloratadine film-coated tablets produced by 
«Borshchahivskiy CPP», Ukraine, and might not be suitable for validation of analytical procedures 
for desloratadine assay in film-coated tablets of other composition and/or manufacture. 
The prospects for the further research. Considering those above, further, it seems rea-
sonable to combine the SPhU metrological approach with the USP recommendations for quality 
assurance of analytical results. 
5. Conclusions 
1. The procedure for assay of desloratadine in film-coated tablets «Alerdez» with con-
tent limits of ±5 % manufactured by PJSC SIC «Borshchahivskiy CPP», Ukraine, by absorption 
spectro photometry in the UV region was validated following the recommendations of the State 
Pharmacopoeia of Ukraine. 
2. All validation characteristics and associated performance characteristics were examined 
in full compliance with ICH recommendations. The analytical procedure has been shown to be 
suitable for its intended use. 
3. The uncertainty of the analytical results and bias ensure acceptable reliability of the deci-
sion on medicine compliance with specifications.
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